Please assess the completion status of the following clinical trial:

Trial Title: The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. The patient have age more equal 18 year on enrollment date. 2. The patient get the dialysis of 3 times per week 3. The parathyroid hormone level greater than or equal to 800 pg per mL during the screening 4.The calcium level in the blood is greater than or equal to 9 mg per dL.~Exclusion Criteria:~1. The patient had parathyroid gland surgery.~2. The patient have a history of seizures within 12 weeks before randomized.~3. The patient is scheduled for surgery the kidney~4. The patient will expected parathyroid gland surgery within 6 months~5. The liver function have abnormalities, including SGOT, SGPT, more than two fold~6. The patient had history received a drug of bisphosphonates group or expected to be received during the study.~7. The patient had a history of cancer. Pregnant women. Lactating women. And with sepsis -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Regpara (Type: EXPERIMENTAL): calcium sensing receptor agonist

Based on this trial design, predict the completion outcome and termination type (if applicable).